 |
|
Controversies in
Anemia Management
How well does the oncology nursing audience understand the latest issues
and controversies in anemia management? A nationally recognized thought
leader will review the most pressing topics as they relate to CRA, including
flexible dosing schedules of erythropoietic agents, appropriate use of
concomitant iron, prevention and management of anemia in patients
undergoing surgery followed by chemotherapy, and anemia prevention and
management in patients with hematologic malignancies. This presentation will
be followed by a continuing education game show program titled Deal or No
Deal, which will test participants’ understanding of CRA. This latest craze in
game shows has never been played in such a setting before, so participants
are in for a one-of-a-kind type of learning experience. The winning team will
have the opportunity to donate $1,000 to its cancer-related charity of choice.
|
| |
|
|
|
|
Changing Paradigms in the Treatment of Multiple Myeloma: Nurse-Centric Case-Based Discussions
Clinical research has identified new agents and combinations of agents that demonstrate superior efficacy against MM. As a result, many patients with MM can now anticipate surviving for decades rather than years. An advanced practice oncology nurse expert will provide an overview of current therapeutic strategies and novel agents used in the treatment of MM. Novel agents will be described using 3-D video animations. A leading hematology physician will present recent clinical trial data regarding the use of these therapies in clinical practice. The program will include a discussion on the management of major toxicities associated with these therapies using case studies submitted by oncology nurses from around the country.
|
| |
|
|
|
|
Tumor Lysis Syndrome and Venous Thromboembolic Disease: Oncology Nurse-Centric Case-Based Discussions
The introduction of novel cancer therapeutics has created an increasingly challenging environment for oncology nurses in the endeavor to prevent and optimally manage treatment-related complications. TLS and VTE are two complications that are of particular concern to oncology nurses and cancer patients alike. Prophylaxis and management of such complications are a primary responsibility of the oncology nurse. In this symposium, case presentations of patients with cancer will be used to facilitate an interactive discussion with program participants on guideline-based approaches to prophylaxis and management of VTE and TLS. Cases will highlight the latest research related to preventing, diagnosing, and treating such disorders.
|
| |
|
|
 |
|
Clinical Management of AML/MDS in the Older Adult: Expert Responses to Oncology Nurse-Submitted Cases
Both AML and MDS represent myeloid stem cell malignancies common in older adults. Recent scientific advances in both diseases have been robust, resulting in the identification of key molecular, immunological, and hematological characteristics that are similar and distinct in these two diseases. Novel agents have been developed and administration guidelines refined, thereby expanding therapeutic options for patients who are unable to tolerate aggressive systemic therapies, specifically, older adults. Accurate diagnosis and differentiation of de novo AML from MDS that has evolved into AML are of particular importance in the older patient when selecting treatments that can influence clinical outcomes.
|
| |
|
|
|
|
Chronic Myeloid Leukemia: Expert Reponses to Frequently Asked Questions
The success of imatinib and second-generation tyrosine kinase inhibitors (TKIs) has resulted in a paradigm shift in the treatment of chronic CML. The Institute for Medical Education & Research (IMER) has compiled questions submitted by oncology nurses at various IMER-sponsored educational symposia. These questions cover topics such as TKI mechanisms of action, monitoring responses, current and future research directions, and nursing management strategies for patients receiving TKI therapy. During this interactive, 2-hour educational program, expert faculty will address these and other frequently asked questions.
|
| |
|
|
|
|
Venous Thromboembolic Disease: Oncology Nurse-Centric Case-Based Discussions
Patients with cancer are exposed to numerous disease- and treatment-related complications that, if not addressed appropriately, can become life threatening. One of the most serious complications is VTE, which includes deep vein thrombosis and pulmonary embolism. In this symposium, an overview of VTE will be provided and the latest treatment strategies discussed. Selected cases will highlight the latest research on the prevention, diagnosis, and treatment of VTE.
|
| |
|
|
|
|
Cancer Research Highlights 2008: Hematologic Malignancy Research Highlights
Day 1 of this first-of-its-kind conference for APNs and oncology nurses will provide a comprehensive overview of the clinical research landscape of hematologic malignancies. Topics will include chronic myeloid leukemia, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, multiple myeloma, and myelodysplastic syndrome. Day 2 of this conference for APNs and oncology nurses will highlight current trends in the treatment of solid tumors and the clinical application of recent research developments.
Breakthrough data on treatment approaches for hematologic malignancies will be presented by nationally recognized thought leaders. The conference will begin with a brief overview of select statistical concepts as a basis for understanding published research reports to be presented during the 2-day meeting. The remainder of Day 1 will focus on specific hematologic topics listed below. Each presentation will include an overview of current research to be followed by a case-based discussion illustrating how the data presented can be incorporated into clinical practice.
|
| |
|
|
|
|
CME Activity for OncologistsThe Future Is NOW for the Treatment of Chronic Myelogenous Leukemia!
The treatment of CML dramatically changed with the introduction of imatinib, a tyrosine kinase inhibitor (TKI) that targets the BCR-ABL chromosomal abnormality—a hallmark feature of CML. Prior to the development of TKIs, the aim of treatment was to control and palliate patients with CML; now there is curative intent. With the proper selection of treatments, physicians can influence survival outcomes. Despite high response rates to imatinib, many patients with the chronic phase of CML will have persistent disease and ultimately relapse. There are several options available to patients who have relapsed or are intolerant to imatinib, including the use of second-generation TKIs such as dasatinib and nilotinib. With the introduction of these agents, several new clinical questions have emerged. Should second-generation TKIs replace imatinib as upfront therapy? What is appropriate disease monitoring? How do you treat a patient with increasing qPCR levels in the absence of a cytogenetic or hematologic relapse? What are the indications for switching to second-line therapy and what are the implications of particular mutations on the choice of second-line therapy? How long should a second-line TKI be used before trying other strategies? What is the role of stem cell transplantation? In light of such new clinical questions, this program is intended to provide attendees with a review of appropriate front-line and salvage therapies as well as strategies for effectively monitoring response to treatment. Attendees are invited to bring their own challenging CML patient cases for expert and group discussions.
|
| |
|
|
 |
|
A leading hematology advanced practice nurse will deliver a 3-D video animated presentation describing the pathophysiology of CML and the mechanisms of action of first-and second-generation BCR-ABL directed tyrosine kinase inhibitors (TKIs). A physician key opinion leader will provide an update on emerging therapeutic options. Specific questions to be addressed include: Will the new, more potent secondgeneration TKIs eventually replace imatinib as front-line therapy? Is there any role for combining treatments? Where does allogeneic bone marrow transplantation fit into the new treatment paradigm? Are newer, agents being developed for CML? Finally, an APN will lead a case-based discussion on side-effect management and special circumstances affecting patients in the chronic, accelerated, and blast phases of the disease.
|
| |
|
|
|
|
This activity will highlight recent changes in the standard of care for MM. Clinical research has identified new agents and combination regimens that demonstrate superior efficacy against MM. As a result, many patients with MM can anticipate surviving for decades instead of years. A hematology advanced practice nurse will provide an overview of the current treatment landscape, including the use of novel agents. The mechanisms of action of these novel agents will be illustrated using 3-D animations. In addition, a leading hematology physician will discuss recent clinical trial results and their implications on clinical practice. The program will conclude with a case-based discussion on the major toxicities associated with these agents as well as appropriate management strategies.
|
| |
|
|
 |
|
Management of cancer treatment side effects is among
the key roles of nurses caring for cancer patients. CINV,
CIA, and OM are among the most common and
distressing toxicities of cancer treatment. They
negatively impact patients’ quality of life and may cause
treatment delays and interfere with patients’ outcomes.
In this interactive game show symposium, a panel of
thoughtleaders in oncology supportive care, who are
cancer survivors themselves, will discuss key aspects of
CINV, CIA, and OM management. Appropriate patient
education will be highlighted.
|
| |
|
|
 |
|
Monoclonal Antibody Therapy for Follicular Non-Hodgkin's Lymphomas:
Moving Toward a Cure
The clinical development of monoclonal antibodies represents
a major advancement in the treatment of patients with
follicular NHL. In this educational symposium, the principles of
antibody-based therapy will be described in 3-D video
animation. This presentation will be followed by a historical
review of follicular NHL treatment options and the current
treatment landscape. An overview of how treatment decisions
are made based on prognostic parameters will be given. A
case presentation will facilitate discussions on the appropriate
nursing management of patients with follicular NHL receiving
monoclonal antibody therapy. Oncology nurses' understanding
of presented issues and their own practice patterns will be
questioned via audience response technology.
|
| |
|
|
 |
|
|
| |
|
|
 |
|
|
|
| |
|
